Overview

Italian Multicenter Study Comparing FOLFOXIRI Versus Gemcitabine as Adjuvant Treatment for Resected Pancreatic Cancer

Status:
Unknown status

Trial end date:
2018-12-01

Target enrollment:

Participant gender:

Summary

Patients with resected pancreatic cancer who fulfill the selection criteria will be randomized to receive one of the two treatment arms for a period of 6 months: Gemcitabine, the standard arm, or FOLFOXIRI (the combination of 5-Fluorouracil/Folinic Acid, Oxaliplatin and Irinotecan), the experimental arm. A total of 310 patients will be enrolled in about 50 Italian centers.

Phase:

Phase 3

Details

Lead Sponsor:

Azienda Ospedaliero, Universitaria Pisana

Treatments:

Fluorouracil
Gemcitabine
Oxaliplatin